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Objective: This systematic review and meta-analysis aimed to summarize the available 
evidence regarding circulating kisspeptin and anti-müllerian hormone (AMH) and the 
homeostasis model assessment of insulin resistance (HOMA-IR) index in adolescents 
and women with and without polycystic ovary syndrome (PCOS).   
Method: We performed a comprehensive literature search in Medline, Embase, 
Cochrane, Scopus, and Web of Science for studies evaluating circulating kisspeptin 
levels in women with and without PCOS published until September 24th, 2020.  Co-
primary outcomes were the HOMA-IR index and AMH. The quality of included studies 
was assessed using the Newcastle-Ottawa Scale. Random-effects models were used to 
estimate outcomes, and effects reported as mean difference (MD) or standardized MD 
(SMD) and their 95% confidence interval (CI). The systematic review and meta-analysis 
was registered in the International Prospective Register of Systematic Reviews 
(PROSPERO) as number CRD42020205030. 
Results: We evaluated 18 studies including, 1,282 PCOS cases and 977 controls. 
Participants with PCOS were younger (MD=-2.38 years, 95%CI -4.32 to -0.44), with 
higher BMI (MD=1.16, 95% CI 0.54 to 1.78), waist-to-hip ratio (MD=0.04, 95%CI 0.02 to 
0.05), circulating kisspeptin (SMD=1.15, 95%CI 0.68 to 1.62), luteinizing hormone 
(SMD=1.29, 95%CI 0.76 to 1.83), AMH (SMD=0.97, 95%CI 0.60 to 1,34), total 
testosterone (SMD=2.48, 95%CI 1.73 to 3.23), free testosterone (SMD=1.37, 95%CI 
0.56 to 2.17), and dehydroepiandrosterone sulfate (SMD=0.72, 95%CI 0.32 to 1.13) 
levels, and Ferriman-Galweg score (SMD = 5.08, 95%CI 2.76 to 7.39), and lower sex 
hormone-binding globulin level (SMD=-1.34, 95%CI -2.15 to -0.52). Besides, 
participants with PCOS had higher HOMA-IR index (SMD=0.76, 95%CI 0.35 to 1.17), and 
circulating insulin (SMD=0.75, 95%CI 0.30 to 1.19), leptin (SMD=2.82, 95%CI 1.35 to 
4.29), and triglycerides (SMD=2.15, 95%CI 1.08 to 3.23) levels than participants 
without the syndrome. The meta-regression did not identify significant factors 
influencing circulating kisspeptin.  
Conclusion: Patients with PCOS showed higher kisspeptin, LH, insulin, AMH, and 
androgen levels and HOMA-IR index, and lower sex hormone-binding globulin levels 
than those without the syndrome.   
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AMH: Anti-müllerian hormone; BMI: Body mass index; CI: Confidence interval; DHEA-S: 
dehydroepiandrosterone sulfate; FSH: Follicle-stimulating hormone; GnRH: gonadotrophin-
releasing hormone; HDL: High density lipoprotein; HOMA-IR: Homeostatic model assessment 
of insulin resistance; IQR: Interquartile range; LDL: Low density lipoprotein; LH: Luteinizing 
hormone; MD: Mean difference; NOS: Newcastle–Ottawa Scale; PCOS: polycystic ovary 
syndrome (PCOS); SD: Standard deviation; SHBG: Sex hormone-binding globulin; SMD: 





Kisspeptins are a group of brain neuropeptides initially described as metastasis 
suppressors [1]. The kisspeptin precursor has 145 amino acids that, by proteolysis, produce 
kisspeptin-54 (also know as metastin) that is considered the active product. Kisspeptin 13 and 
kisspeptin-14 are products from the degradation of kisspeptin-54 [2,3]. Kisspeptin (encoded 
by KISS1) influences gonadotrophin-releasing hormone (GnRH) and luteinizing hormone (LH) 
secretion and might contribute to the development of some features of the PCOS [4,5]. 
Although kisspeptin is expressed in discrete brain regions, it is also present in peripheral 
tissues like fat, liver, and pancreas [4]. Women with PCOS have an increased expression of 
kisspeptin receptors in granulosa lutein cells [6]. Clinical studies reported variable and 
heterogeneous results concerning circulating kisspeptin levels in women with PCOS 
[7,8].  
PCOS is associated with different degrees of hypothalamic-pituitary-ovarian 
axis function disorders, hyperandrogenemia, excessive body weight, insulin resistance, 
and genetic factors [9-12]. The prevalence of insulin resistance is higher in women with 
PCOS than in age- and weight-matched women without it [13,14], being about 30% 
and 70%, respectively, in lean and obese women with PCOS [13]. On the other hand, 
women with PCOS display increased circulating anti-müllerian hormone (AMH) that 
correlates with the number of antral follicles, and the AMH measurement diagnostic 
efficacy is superior to follicular count [15]. Besides, it seems to be a specific PCOS and 
reproducible marker from one menstrual cycle to another [16].  Metabolic syndrome 
components and indexes of insulin resistance, including homeostasis model 
assessment IR index (HOMA-IR), are frequently altered in patients with PCOS [10,11]. 
This systematic review and meta-analysis aim to study kisspeptin levels in patients with 
PCOS, to assess possible associations between kisspeptin and insulin resistance and 




This study was undertaken following the Meta-Analysis Of Observational 
Studies in Epidemiology (MOOSE) Group Recommendations [17]. The protocol was 
registered with the international Prospective Register of Systematic Reviews 
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(PROSPERO: CRD42020205030). A formal institutional review board approval was not 
required, since this analysis consisted of the pooling of published studies. 
 
Search strategy 
A literature search was performed on PubMed/Medline, Scopus, Cochrane, 
Web of Science, and Embase databases, using a combination of the following terms 
and their synonyms: “polycystic ovary syndrome”, “Stein-Leventhal syndrome”, 
“kisspeptin”,  and “metastin”. The full PubMed search strategy using Boolean 
operators AND or OR is shown in Appendix 1, eMethod. The search included articles in 
any language from initial publications of human kisspeptin measurements in 2005 until 
September 24th, 2020. Found abstracts were pooled into an EndNote X7.2 (EndNote, 
Clarivate Analytics, Philadelphia, Pennsylvania, United States) to identify and remove 
duplicate records. Besides, references from selected articles and Google Scholar were 
screened for additional potential publications.  
 
Eligility criteria and outcomes of interest   
This systematic review and meta-analysis include prospective and retrospective 
observational studies assessing circulating kisspeptin levels and endocrine, metabolic, 
and biochemical outcomes in non-pregnant adolescents and women, with and without 
PCOS, irrespective of age, parity, ethnicity, country of origin, publication date, and 
language.  Studies reporting women with other clinical or biochemical forms of 
hyperandrogenism, diabetes or chronic diseases, metabolic alterations, or receiving 
hormone treatments were excluded. The PI(E)COS (Population, Intervention or 
Exposure, Comparators, Outcomes, Study Design) criteria were developed a priori to 
guide the scope of the review, along with the procedures, selection, and synthesis of 
the literature search. Studies were eligible if they met the following inclusion criteria: 
Population: non-pregnant adolescents and women not receiving any treatment. 
Intervention/Exposure: PCOS diagnoses reached by the revised Rotterdam 
ESHRE/American Society of Reproductive Medicine Criteria or other internationally 
recognized scientific organizations [18-20]. Comparator: participants without PCOS. 
Outcomes: The primary outcome was circulating kisspeptin level, and co-primary 
outcomes were HOMA-IR index and AMH levels. Secondary outcomes: reproductive 
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hormones, androgen-related endpoints, and glucose and lipid metabolites. Study 
design: observational studies including patients with all types and stages of PCOS.  
 
Study selection and data extraction 
We included prospective and retrospective observational studies reporting 
circulating kisspeptin in non-pregnant participants with and without PCOS. Studies 
reporting clinical, endocrine, metabolic, or biochemical outcomes of interest, such as 
body mass index (BMI), waist-to-hip ratio, HOMA-IR, insulin, leptin, reproductive 
hormones, androgens, glucose, and lipid metabolites were eligible for inclusion. 
Exclusion criteria were: (a) Circulating kisspeptin concentration was not available or 
could not be extracted from the study groups; (b) no appropriate control group; (c) 
participants receiving any treatment that might modify endocrine or metabolic 
outcomes; and (d) presence of another endocrine, metabolic or chronic disorders 
different from PCOS. Authors were contacted if supplementary information or 
clarification was required to analyze study eligibility. 
Three of the authors (LO, MTLB, FRPL) independently evaluated full-text articles 
for compliance with inclusion and exclusion criteria. Disagreements were managed 
through discussion with all authors to reach a consensus. Extracted data included the 
year of publication, country of study conduction, the sample size for PCOS and control 
groups, participants characteristics, and outcomes per group. Data extraction was 
independently performed by 2 authors (LO, RSC) and disagreements were solved by a 
discussion with all authors. 
 
Risk of bias assessment 
The risk of bias of selected studies was assessed independently by two authors 
(GRPR, MTLB) using the Newcastle–Ottawa scale (NOS) [21]. The NOS consists of three 
parameters of quality: selection, comparability, and outcome assessment. The NOS 
assigns a maximum of four points for selection, two points for comparability, and three 
points for exposure or outcome. NOS scores of ≥7 were considered as high-quality 
studies and NOS scores of 5–6 were considered moderate quality. Any discrepancies 




Statistical analyses     
Effects of the PCOS on outcomes were described as mean differences (MDs) or 
standardized mean differences (SMDs) and their 95% confidence interval (CI). MDs 
were used for age and BMI whereas all other outcomes were pooled as SMDs since the 
heterogeneity of the PCOS, studied population, lifestyle differences (including nutrition 
and physical activity), and laboratory differences. Studies reporting medians (m), and 
interquartile ranges (IQR), means were estimated by x=(a+2m+b)/4, where m is 
median and a and b are P25 and P75, respectively [22]. Standard deviations (SDs) were 
estimated using SD=IQR/1.35. When median and ranges were provided, the mean was 
estimated by x=(a+2m+b)/4 using the values of the median (m), the smallest and 
largest value (a and b, respectively); SD was estimated by SD=range/4 if the sample 
size was <70 and SD=range/6 if the sample size was >70 [23] (GRPR, FRPL). The fixed-
effect model was initially planned if moderate or lower heterogeneity (I2 ≤ 65%) was 
found. If I2 > 65%, the random-effect model was adopted. Assessment for among-study 
heterogeneity was performed by calculating I2: An I2 value of 0-30% define low 
heterogeneity, 30-65 % moderate heterogeneity, and >65 % substantial heterogeneity 
[24].  A p < 0.1 for the Chi2 test was defined as an indicator of heterogeneity; a Tau2 >1 
was defined as the presence of substantial statistical heterogeneity. The effects of 
clinical and statistical heterogeneity from meta-analyses were tested by the exclusion 
of one or several studies sufficed to decrease heterogen eity [25,26].  
Calculated PCOS  mean age, mean BMI, and mean HOMA-IR were pre-specified 
for subgroups analyses. We predefined subgroup for exploring potential sources of 
heterogeneity by (i) mean age groups, (ii) mean BMI groups, and (iii) mean HOMA-IR 
index (GRPR, FRPL, JS).  Meta-regression analyses was used to explore kisspeptin 
heterogeneity (JS). Potential publication bias was estimated by the Begg’s funnel plot 
[27] and the Egger’s linear regression test [28].   
Statistical analyses were conducted using Review Manager (RevMan 5.3; 
Cochrane Collaboration, Oxford, UK) and STATA software (version 10.0; College 
Station, TX, USA).  
 
Results 




After the removal of duplicates, a total of 150 abstracts were identified through 
search engines, and one additional doctoral thesis was identified by manual search. 
Twenty-eight full-text items were evaluated for eligibility. Five  papers did not report 
separated information for control groups, 4 included duplicate information, and one 
did not report the primary outcome (Figure 1). Finally, a total of 18 studies were 
evaluated for qualitative and quantitative assessment [29-47].  
We make an effort to include all available studies or complementary 
information by contacting some authors. Dr. Zahraa H Al-Jelawy kindly provided a full 
complementary document (a doctoral thesis [30] of the article [29]. Dr. Huiying Zang 
provided the mean ages ± SD results not included in the full-publication [47]. Dr. Xiaoli 
Chen informed us that a publication in the Chinese language [48]  was a preliminary 
article of the final publication in English [34]. We also contacted the correspondent 
author of 4 papers published over years [35, 49-51] without getting any response. 
Therefore, we excluded earlier publications to ensure the use of only the largest and 
most recent participants and to prevent data set inflation [35]. 
 
Characteristics of included studies 
The 18 selected studies included 1,282 participants who suffer PCOS and 997 
controls, published between 2006 [44] and 2020 [35, 39, 42] (Table 1). PCOS sample 
sizes across studies ranged from 20 [33] to 250 [37]. The PCOS diagnosis followed (i) 
the Rotterdam criteria in 17 studies [29-43, 45-47], and (ii) one study was based on the 
association of chronic anovulation (< 6 cycles in 12 months) with hyperandrogenemia 
[44]. Six studies were carried out in Turkey [33, 37, 38, 41,42,47},  two in China [34, 
46], two in Iraq [29, 39], and one in each of the following countries: Bulgaria [43], 
Egypt [45], Ghana [31], Greece [44], Korea [40], Kuwait [36], Saudi Arabia [35] and Sri 
Lanka [32]. Table 1 displays information on the location and period of study, number of 
participants, mean age and BMI of participants with and without PCOS, as well as the 
main findings of studies meta-analyzed. Women with PCOS were younger than those 
without the syndrome (Table 2; Fig. 2A), had higher BMI (Table 2; Fig. 2B), and higher 




Risk of bias assessment  
Using the NOS scale, 13 studies were identified as high-quality [35-47], and the 
other five of moderate quality [29, 31-34] (Appendix A, eSupplementary Table 1). All 
publications identified the study population, patients were representative of average 
PCOS cases, and controls were derived from the same population as cases. In all 
studies, secure patient records were used for the ascertainment of PCOS and 
assessment of outcomes.  
 
Meta-analyses of outcomes  
Kisspeptin and reproductive homones 
In 18 studies (n=2,259), circulating kisspeptin was significantly increased in 
women with PCOS as compared to control women (Table 2; Fig. 3A). In 16 studies 
(n=2,017), circulating LH was significantly increased in women with a previous 
diagnosis of PCOS (Table 2; Fig. 3B). In 15 studies (n=1,880), circulating FSH was not 
different in women with and without PCOS (Table 2; Fig. 3C). In 5 studies (n=743), 
circulating AMH was significantly higher in women with PCOS (Table 2; Fig. 3D). In 5 
studies, there were no differences for both prolactin (Table 2; Fig. 3E), and in 8 studies 
estradiol between women with and without PCOS (Table 2; and Figure 3F). There were 
high heterogeneity of effects on outcomes across studies (I2 76%-98%; Table 2). 
 
Androgen-related outcomes 
In 14 studies (n= 1802), total testosterone was significantly increased in 
participants with PCOS (Table 2, Figure 4A). In 7 studies (n = 999), free testosterone 
was increased in participants with PCOS (Table 2, Figure 4B). In 9 studies (n = 1297), 
DHEA-S was significantly increased in participants with PCOS (Table 2, Figure 4C). In 7 
studies (n = 999) SHBG, was significantly reduced in participants with PCOS (Table 2, 
Figure 4D). Finally, in 5 studies (n = 1037,) the modified Ferriman-Gallweg score was 
significantly increased in participants with PCOS (Table 2, Figure 4e). There were high 
heterogeneity of effects on these outcomes across studies (I2 91%-99%; Table 2). 
 
Glucose and insulin-related outcomes 
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In 11 studies (n = 1593), glycemia was not significantly different in participants 
with and without PCOS (Table 2, Figure 4A). In 10 studies (n = 1398), the HOMA-IR 
index was significantly increased in participants with PCOS (Table 2, Figure 4B). In 8 
studies (n = 1104), mean circulating insulin was significantly increased in participants 
with PCOS (Table 2, Fig. 4C). In four studies (n = 832), circulating leptin was significantly 
increased in women with PCOS (Table 2; Fig. 3D). There was a high heterogeneity of 
effect on these outcomes across studies (I2 92%-98%; Table 2). 
 
Lipid-related outcomes 
In 4 studies (n = 957) there were no significant differences in total cholesterol, 
HDL-cholesterol and LDL-cholesterol (Table 2; Figures 6A, 6B, 6C) between participants 
with and without PCOS. In four studies (n = 1045) triglycerides were significantly 
increased in participants with PCOS (Table 2; Figure 6D). There was a high heterogenity 
of effects on lipid outcomes across studies (I2 95%-100%; Table 2).  
 
Subgroup analyses and meta-regression 
Evaluation of subgroup effects on circulating kisspeptin matched studies and 
not matched studies by the mean age of studied groups (I2 = 97%) displayed a similar 
trend with higher levels in patients with PCOS (eSuplementary figure 1). Subgroup 
analysis of circulating kisspeptin studies matched by mean BMI (I2 = 36%) and not 
matched by mean BMI of studied groups showed higher levels in participants with 
PCOS (I2 = 97%; eSuplementary figure 2). There was not a significant difference in 
subgroup analysis of circulating kisspeptin by matched mean HOMA-IR index with a 
difference < 0.60 (I2 = 87%) whereas non-matched mean HOMA-IR (difference > 0,70) 
displayed a significant difference (I2 = 19%; eSuplementary figure 3). The results of 
subgroup of kisspeptin meta-analysis showed moderate heterogeinity for studies 
matched by mean age, mean BMI and HOMA-IR index <0.60. 
 Meta-regression analyses showed that are no influences of age, HOMA-IR 
index, circulating insulin, LH, and anti-müllerian hormone on circulating kisspeptin in 
women with PCOS (eSuplementary Figures 4A, 4B, 4C, 4D and 4E, respectively).  
 
Sensitivity analysis  
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 Sensitivity analyses were performed, including the removal of studies one by 
one, for kisspeptin, HOMA-IR index and AMH (Table 3). The I2 values remained high for 
circulating kisspeptin (94% to 96%, n = 18 studies) and HOMA-IR index (80% to 92%), 
whereas for AMH was 61% by deleting the Kaya et al. study [41]. A sensitivity analysis 
for kisspeptin was also performed deleting 4 studies [29,31,32,44] and heterogenity 
was reduced to 67% (eSuplementary figure 4). 
 
Publication bias 
Funnel plots of outcomes available in more than 10 studies (kisspeptin and 
HOMA-IR) showed that there was asymmetry of points for kisspeptin (Egger test 
=7.535, p<0.001) and symetry for HOMA-IR index (Egger test = 0.136, p=0.902). When 
3 studies [29,31,32] with suspected publication bias for kisspeptin, the remaining 15 
studies did not display publication bias ( Egger test = -0.172, p=0.863; eSupplementary 
figure 5, eSuplementary table 2). Funnel plots and Egger’s tests were also calculated 
for HOMA-IR index (eSuplementary figure 6, eSupplementary table 2). There were 
publication bias for circulating LH, FSH, and total testosterone levels (eSuplementary 




Meta-analyzed PCOS patients were younger with higher BMI and waist-to-hip 
ratio in comparison to participants without the syndrome. They had increased 
circulating kisspeptin, LH, AMH, total and free testosterone, DHEA-S, insulin, and leptin 
whereas the SHBG was lower than in the control group. They also had increased 
HOMA-IR index, and circulating insulin, leptin, and triglyceride levels. There were no 
significant differences for circulating FSH, estradiol, prolactin, glucose, total 
cholesterol, HDL-cholesterol, and LDL-cholesterol. Meta-regression analysis indicates 
that kisspeptin is not influenced by age, HOMA-IR index, circulating insulin, LH, and 
AMH. 
In this meta-analysis of 18 studies, circulating kisspeptin levels were 
significantly higher in 1282 PCOS cases than in 977 participants without the syndrome. 
Kisspeptin was initially described as a suppressor of metastasis in human melanoma 
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and named metastin [52]. It acts on an orphan G-protein coupled receptor (GPR-54) 
and is present in the central nervous system and the pituitary gland [53]. New research 
has now shown that the novel kisspeptin receptor agonist MVT-602 mediates the 
increase of LH levels in healthy women and those with PCOS or hypothalamic 
amenorrhea [54].  Hypothalamic kisspeptin has a regulatory effect on GnRH neurons to 
control the reproductive axis, and its release is under the influence of nutrients and 
energy reserve [55]. In both rodents and humans, kisspeptin is also present in limbic 
brain regions [56]. Kisspeptin neurons may integrate information from other 
hormones, environmental factors, stress, and metabolic variables. Experimental and 
clinical evidence suggests that kisspeptin may switch the onset of puberty [57,58]. 
Both the neurokinin B receptor and the kisspeptin receptor are also present in normal 
human granulosa cells, while their lower expression alters normal follicle development 
[59].  Therefore, the increased kisspeptin levels detected in PCOS patients may act on 
both the pituitary and the ovaries.  Preliminary studies suggest that kisspeptin 
administration to women with PCOS partially stimulates gonadotropins and ovulation 
[60]. However, kisspeptin does not neutralize menstrual dysfunction and long cycles 
[61].  
In the present study, PCOS patients showed significantly increased AMH levels 
when compared to non-PCOS subjects. AMH is s a dimeric glycoprotein secreted by the 
granulose cells that regulates folliculogenesis and is a marker of the number of antral 
follicles [62, 63].  In women with normal ovaries, high AMH has an inhibitory effect on 
antral follicle development while low serum AMH is associated with  ovulation, 
pregnancy rate and greater live birth rates [64].  AMH levels are related to increased 
fasting glucose and insulin levels , testosterone, and BMI in PCOS patients  [65]. AMH 
values higher than 5.1 ng/mL are considered a surrogate marker of hyperandrogenism 
since positively correlates with total testosterone, 17-hydroxyprogesterone, and LH 
[66].  AMH levels are highest when patients have all three major characteristics of 
PCOS (menstrual disorders, hyperandrogenism, and ultrasound evidence of polycystic 
ovaries) [65,67].   
PCOS menstrual disfunction and amenorrhea are associated with increases in 
circulating LH, androgens, and insulin, and reduced SHBG [68].  The increased LH levels 
in PCOS patients may be a consequence of the sustained increase of kisspeptin release 
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that might promote alterations on the hormone feedback mechanism and persist 
permanently disrupted. Besides, there is a correlation between AMH and kisspeptin in 
PCOS patients that does not exist in normal women [42]. We found higher levels of 
circulating glucose, insulin and leptin, as well as the HOMA-IR index,  BMI, and waist-
to-hip ratio in patients with PCOS as compared to the control group.  The full-length 
kisspeptin has 54 aminoacid may regulate glucose metabolism, although several 
smaller peptides (with 10, 13, and 14 aminoacids) are also produced in vivo with a 
similar biologic effect to the principal kisspeptin-54 [1]. In non-diabetic subjects, higher 
kisspeptin levels are associated with hyperinsulinism independently of sex, age, 
adiposity post-load glucose, and insulin sensitivity, and is inversely correlated with BMI 
and waist circumference [69]. In normal subjects, kisspeptin administration does not 
alter gut hormone, appetite, and food consumption [70]. 
Abdominal fat tissue accumulation during puberty has been postulated that is 
central in the progression of PCOS and alterations of kisspeptin, hyperandrogenism, 
and insulin resistance which at the same time increases the abdominal fat deposition 
[71,72].  Previous studies demonstrates that PCOS women have significantly higher 
levels of triglycerides closely related to waist circumference and insulin resitance [73]. 
The alteration of lipid metabolism in PCOS patients are related with the risk of insulin 
resistance and higher HOMA-IR [74]. In non-diabetic subjects, these endocrine and 
metabolic responses have been associated with circulating kisspeptin levels [56]. 
Animal experiments and human studies have demostrated associations between 
circulating kisspeptin levels and glucose metabolism and insulin secretion by altering 
adiposity [70]. A positive correlation between kisspeptin levels and HOMA-IR index has 
been reported in women with PCOS [43]. However, our meta-regression of meta-
analyzed women showed that circulating kisspeptin is not influenced by age, HOMA-IR 
index, and AMH.  
Our meta-analyses also showed that PCOS patients had increased circulating 
total and free testosterone, and DHEA-S levels, and reduced levels of DHEA-S. 
Circulating androgen levels are bound to proteins that determine distribution, 
metabolism, and biological effects. The unbound fraction of androgens are responsible 
for the caption on target organs and functions. SHBG is the principal plasma transport 
protein for sex steroids, regulating the androgen bioavailability to target tissues [75]. 
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This meta-analysis has the strength that PCOS patients were diagnosed 
according to standardized international scientific recommendations, including 1282 
cases, and without possible duplicated populations. Since published studies were from 
2006 to 2020 measuring hormones and metabolic outcomes with different methods, 
we calculated all those outcomes as SMD to neutralize the risk of bias related to 
methodological laboratory evolution. Our meta-analysis fills some gaps and  
controversies from individual studies concerning endocrine and metabolic PCOS 




The high statistical heterogeneity is a limitation of our study that may be due to 
(i) the small sample size, varying from only 20 to 250 women with PCOS, which may 
cause unexpected sampling error, (ii) to variable age of participants and PCOS 
characteristics; (iii) difference in nutrition and physical activity. Different PCOS 
phenotypic variants may likely have different levels of kisspeptin since its short half 
degrees of insulin resistance and hyperandrogenism. Physical activity is also a 
determinant of the endocrine and metabolic status of patients with PCOS that was not 
reported in studies meta-analyzed. Exercise training and physical activity in PCOS may 
have benefits, improving the anthropometric measurements such as BMI, waist 
circumference, and free androgen index, whereas metabolic parameters are not 
improved [62,79,80].  
New studies are needed to answers questions and doubts generated by the 
ongoing meta-analysis, and to clarify relationships among kisspeptin, AMH, insulin 
resistance, and androgens. Future clinical studies should clearly define PCOS women 





In comparison to controls, adolescents and women with PCOS have high 
kisspeptin levels associated with increased insulin, LH, AMH, total and free 
testosterone, and DHEA-S, and lower SHBG levels. The HOMA-IR index, and circulating 
insulin, leptin, and triglycerides are also higher in patients with PCOS. The meta-
regression analysis did not identify factors participating in kisspeptin regulation and 
metabolism in PCOS patients. 
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Fig. 2. Forest plots comparing participants with and without polycystic ovary syndrome 1 
(mean difference), from the top to the bottom, for age (Fig. 2A), BMI (Fig. 2B), and waist-2 
to-hip ratio ratio (Fig. 2C).  3 
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Fig. 3. Forest plots comparing participants with and without polycystic ovary syndrome 1 
(standardized mean difference), from the top to the bottom, for kisspeptin (Fig. 3A), 2 
luteinizing hormone (LH; Fig. 3B), follicle-stimulating hormone (FSH, Fig. 3C), anti-3 
müllerian hormone (Fig. 3D),  prolactin (Fig. 3E), and estradiol (Fig. 3F).  4 
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Fig. 4. Forest plots comparing participants with and without polycystic ovary syndrome 1 
(standardized mean difference), from the top to the bottom, for total testosterone (Fig. 2 
4A), free testosterone (Fig. 4B), dehydroepiandrosterone sulphate (DHEA-S, Fig. 4C), sex 3 
hormone-binding globulin (Fig. 4D), and modified Ferriman-Gallweig score (Fig. 4E). 4 
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Fig. 4D. Sex hormone-binding globulin  1 
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Fig. 5. Forest plots comparing participants with and without polycystic ovary syndrome 1 
(standardized mean difference), from the top to the bottom, for glycemia (Fig. 5A),  2 
HOMA-IR index (Fig. 5B), insulin (Fig. 5C), and leptin (Fig. 5D).  3 
 4 
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Fig. 6. Forest plots comparing participants with and without polycystic ovary syndrome 1 
(standardized mean difference), from the top to the bottom, for total cholesterol (Fig. 2 
6A), HDL-cholesterol (Fig. 6B), LDL-cholesterol (Fig. 6C), and triglycerides (Fig. 6D).  3 
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Table 1.  Studies comparing serum kisspeptin levels in women with and without polycystic ovary syndrome (PCOS): Study location and period, aim, number of 




Location and period of study. Aim of the 
study  
PCOS participants; age; BMI and 
diagnosis criteria 
Participants without 
PCOS; age and BMI  




Location: Najaf City, Iraq; December 2017 
to September 2018. 
Aim: To study kisspeptin and interleukin 
37 in patients with infertility and PCOS. 
n = 70 women with infertility and 
PCOS.  
Age: 26.97 ± 0.69; BMI: 28.50 ± 
0.55. 
Diagnosis: Rotterdam criteria. 
n = 18 fertile women. 
Age: 33 ± 1.24; BMI 
26.59 ± 0.86. 
Significant higher circulating kisspeptin, cholesterol, 
triglyceride, LDL-C, VLDL-C, hemoglobin and prolactin 
levels in women with PCOS. Significant lower serum 




Location: Accra, Ghana; 2018. 
Aim: To study kisspeptin and other 
hormones in women > 18 years with 
PCOS.  
n = 41 women with PCOS. Age: 32.8 
± 0.9; BMI 30.91 ± 0.78. Diagnosis: 
Rotterdam criteria. 
n = 40 women.   
Age 33.55 ± 1.12; BMI: 
28.83 ± 0.49 
Significant differences in kisspeptin, LH, FSH, 
testosterone and glucose levels.  
Branavan U 
2019 [32]  
 
Location: Colombo, Sri Lanka; period of 
study not stated. 
Aim: To study circulating kisspeptin and its 
polymorphisms. 
n = 55 women with PCOS. Age: 
24.67 ± 0.88; BMI: 26.89 ± 0.72. 
Diagnosis: Rotterdam criteria. 
n = 110 women. Age 
33.80 ± 0.53; BMI: 25.25 
± 0.34 
Serum kisspeptin and testosterone concentrations 
were significantly higher in women with PCOS than 
controls. Sequencing the Kiss1 gene revealed 2 single 
nucleotide polymorphisms. 
Celik N 2018 
[33] 
Location: Istanbul, Turkey; period of study 
not stated. 
Aim: To assess adiponutrin, amylin, 
preptin and kisspeptin in women 
undergoing in vitro fertilization. 
n = 20 infertile women with PCOS. 
Age: 35.3 ± 3.1. BMI = 27.3 ± 4.9 
kg/m2. Diagnosis Rotterdam 
criteria. 
n = 20 infertile women 
with poor ovarian 
response. Age: 35.3 ± 
3.1. BMI: 24.5 ± 5.0. 
PCOS diagnosis: 
Serum kisspeptin levels were negatively correlated with the number 
of retrieved oocytes and pregnancy rates. Amylin and adiponutrin 
have no role in the folliculogenesis, whereas kisspeptin and preptin 
seems to participate in follicle developmental in PCOS women. 
Chen X 2010 
[34] 
Location: Guangdong, China; period of 
study not stated. 
Aim: To study kisspeptin and correlations 
with reproductive and metabolic 
outcomes. 
n = 42 (adolescent n = 19, adult n = 
23). Age: adolescents: 17.89 ± 1.24, 
adults: 26.17 ± 3.45.  
BMI: 21.52 ± 3.7 kg/m2 
PCOS diagnosis: Rotterdam criteria.  
n = 20 participants.  
Age: 18.6 ± 0.68. 
BMI: 20.1 ± 2.3. 
Circulating kisspeptin levels are increased in 
participants with PCOS compared to the control group. 
Kisspeptin levels were positively correlated with serum 
LH and testosterone levels. 
Daghestani 
MH 2020 [35]  
Location: Makkah, Saudi; period of study 
not stated. Aim: To study kisspeptin, LH, 
FSH and KISS1 polymorphisms in women 
with PCOS. 
n = 104. 
Age: 25.1 ± 3.9; 
BMI: 29.5 ± 6.0. PCOS diagnosis: 
Rotterdam criteria.  
n = 109. Age: 25.0 ± 5.6; 
BMI: 29.9 ± 7.3. 
Waist-hip ratio, LH, and LH-FSH ratio were significantly 
higher in PCOS women than controls. BMI, kisspeptin 
and FSH levels exhibited no significant difference 
between groups.  
El-Shehawy 
YM 2016 [36] 
Location: Kuwait; 2010-2012. Aim: To 
study kisspeptin and AMH levels in 
women with PCOS. 
n = 23. Age = 24.4± 1.2; BMI: 
23.4±1.7. 
PCOS diagnosis: Rotterdam criteria. 
n = 19. Age: 27.15 ± 1.7; 
BMI: 22.1 ± 1.5. 
Serum kisspeptin, AMH, LH, testosterone and DHEA-S 
levels were higher in women with PCOS. There were 
correlations between kisspeptin and AMH in women 




OE 2016 [37]   
Location: Izmir, Turkey; December 2011 to 
September 2013. 
Aim: To study kisspeptin, AMH, insulin, 
LH, FSH and steroid hormones. 
n = 250. Age: 23.99 ± 4.63; BMI 
24.32 ± 3.40. PCOS diagnosis: 
Rotterdam criteria. 
n = 150.  
Age: 24.43 ± 4.39;  
BMI: 23.44 ± 4.08. 
 
Serum kisspeptin and leptin levels do not differ 
between PCOS and control women while LH levels and 
LH/FSH ratio were higher in PCOS patients compared 
with controls.  
Gorkem U, 
2018 [38] 
Location: Corum, Turkey; January to 
September 2016. 
Aim: To investigate kisspeptin levels in 
infertile women with different ovarian 
reserve patterns. 
N = 60. Age 27.76 ± 4.65; BMI: 
26.34 ± 4.69. PCOS diagnosis: 
Rotterdam criteria. 
N = 57. Age: 27.9 ± 4.7; 
BMI: 
26.1 ± 5.4. 
Kisspeptin, AMH, LH, total testosterone and DHEA 
levels were higher in infertile women with PCOS as 
compared to women without the syndrome and 




Location: Sulaymaniyah, Iraq; April 2018 
to March 2019.  
Aim: To study kisspeptin levels in women 
with and without PCOS, and the effect of 
obesity and age on this hormone. 
n = 60 infertile women with PCOS. 
Age:  30.09 ± 7.60; BMI: 26.05 ± 
3.76. PCOS diagnosis: Roterdam 
criteria: 
n = 40. Age: 31.6 ± 7.16. 
BMI: 25.93 ± 3.7. 
Serum kisspeptin levels were higher in PCOS patients 
than in those without the syndrome. In women 
without PCOS preovulatory kisspeptin levels were 
higher than in the follicular phase; this difference was 
not present in women with PCOS. The BMI difference 
was not associated with different kisspeptin levels.  
Jeon YE 2013 
[40] 
Location: Yongin, Korea; period of study 
not stated. 
Aim: to evaluate circulating kisspeptin, 
leptin and retinol binding protein 4 (RBP4) 
levels in women with and without PCOS.  
n = 54. Age: 23,72  ± 5,32. BMI: 
23,10 ±  2,76. PCOS diagnosis: 
Rotterdam criteria. 
n = 36. Age: 24.92 ± 
2.94. BMI: 19.77 ± 1.51. 
 
Kisspeptin, leptin and RBP4 levels were significantly 
higher in women with PCOS. In women with PCOS, 
kisspeptin levels were positively correlated with RBP4 
levels.  
Kaya C 2018 
[41] 
 
Location: Istanbul, Turkey; August 2016 to 
June 2017. 
Aim: To study circulating kisspeptin in 
infertile women with PCOS. 
n = 29 infertility and PCOS. Age: 
28.75 ± 3.49; BMI : 28.6 ± 5.08 kg. 
PCOS diagnosis: Rotterdam criteria. 
n = 27. Age: 30.25 ± 
4.66; BMI 26.4 ± 3.32.  
Women with PCOS display higher levels of kisspeptin, 
increased antral follicle count and higher BMI.  
 





Location: Istanbul, Turkey; June 2017 to 
June 2018.  
Aim: To asses serum kisspeptin and AMH 
levels in women with PCOS. 
n = 70. Age:  23.51 ±4.33 
BMI: 24,53 ± 5,22 
PCOS diagnosis: Rotterdam criteria. 
n = 58. Age: 30,88 ± 
5,57; BMI: 22,78 ± 3,48 
There were not significant differences in kisppeptin 
and FSH levels between women with and without 
PCOS. Age, BMI, LH, AMH, DHEA-S, total testosterone, 
glucose and insulin, and HOMA-IR were significantly 




Location: Plovdiv, Bulgaria; period of 
study not stated. 
Aim: To study kisspeptin and galanin-like 
peptide (GALP) roles in the development 
of PCOS. 
n = 87 (BMI ≥ 25, n = 40; BMI <25, n 
= 47).  
Age: 24.99 ± 0.49. BMI: 25.59 ± 
0.65. PCOS diagnosis: Rotterdam 
criteria. 
n = 42 (BMI ≥ 25, n = 20; 
BMI < 25, n =22 )  
Age:  26.65 ± 0.71  
BMI: 24.88 ± 0.89. 
Kkisspeptin and GALP are increased in women with 
PCOS and positively associated with 
hyperandrogenism. In overweight PCOS women 
kisspeptin correlated positively with insulin, 
testosterone and SHBG.  
32 
 




Location: Thessaloniki; Greece; period not 
stated. 
Aim: To study kisspeptin in women with 
and without PCOS and related  metabolic 
disturbances. 
n = 56. Age: 23.97 ±  0.93.  
BMI = 26.83  ± 0.44. 
PCOS diagnosis criteria: chronic 
anovulation (< 6 cycles in 12 
months) and hyperandrogenemia. 
n = 13. Age: 26.85 ± 
1.06. BMI: 32.13 ± 1.85 
(all BMI ≥ 25) 
There were not significant difference in circulating 
kisspeptin in women with PCOS compared to controls. 
Kisspeptin negatively correlated with insulin resistance 





Location: Zagazig, Egypt; period of study 
not stated. 
Aim: To estimate kisspeptin levels in 
women with and without PCOS. 
n = 105. Age: 30.6 ± 6.57. 
BMI: 28.4 ± 7.87 
PCOS diagnosis: Rotterdam criteria. 
n = 90. Age: 32.44 ± 
7.08.  BMI 27.73 ± 6.37 
 
Kisspeptin levels were higher in PCOS patients, 
decreasing with increasing of BMI. Moreover, it was 
negatively correlated to anthropometric measures, 
glycemic and lipid profile. 
Wang T 2019 
[46] 
Location: Tianjin, China; December 2014 
to July 2017. 
Aim: to study kisspeptin and its 
relationship with abnormal metabolism in 
PCOS.  
 
n = 73 PCOS cases seeking treated 
for menstrual disorders or 
infertility. Age: 27.53 ± 5.08. 
BMI: 26.52 ± 5.97. 
PCOS diagnosis: Rotterdam criteria. 
n = 63 women seeking 
assisted reproductive 
techniques due to male 
factors or tubal factors 
Age: 31.96 ± 3.96. BMI: 
22.29 ± 4.31. 
Kisspeptin levels were higher in PCOS women than in 
the control group. Kisspeptin correlated with LH levels, 




Location: Konya, Turkey; period of study 
not stated. 
Aim: to study circulating kisspeptin in 
relation with hormonal and metabolic 
measurements in women with PCOS. 
n = 83 (BMI < 25, n = 42; BMI ≥  25; 
n = 41). 
Age: 21.0  ± 5.0. BMI: 24.5  ± 4.17. 
PCOS diagnosis: Rotterdam criteria.  
n = 66 (BMI < 25,n = 41; 
BMI  ≥ 25, n = 25). 
Age: 24.5 ± 3.5   n= 66 
BMI: 23.1  ± 4.2. 
Women with PCOS had higher kisspeptin levels than 
controls even after controlling for BMI. Kisspeptin had 
positive correlations with glucose, testosterone, 
DHEA-S, and LH; however, kisspeptin negatively 
correlated with SHBG.  
 
AMH: anti-mullerian hormone; BMI: Body mass index; DHEA-S: dehydroepiandrosterone sulphate; FSH: Follicle-stimulating hormone; HOMA-IR: homeostasis model assessments of insulin 




Table 2. Pooled effects reported as mean differences (MDs) or standardized MDs (SMDs) and 
95 % confidence interval (CI) using random effect models and heterogenity (I2) in women with 
and without polycystic ovary syndrome (PCOS). 
Outcome (Figures) Included 
Studies 
Participants 
PCOS / control 
MD or SMD and 95% CI I2 
(%) 
p 
Age (Fig 2A) 18 1282 / 977 MD -2.38 [-4.32, -0.44] 99 0.02 
BMI (Fig 2B) 18 1282 / 977 MD 1.16 [0.54, 1.78] 93 0.0002 
Waist-to-hip ratio (Fig 2 C)  8 757 / 628 MD 0.04 [0.02, 0.05] 92 <0.00001 
Kisspeptin (Fig 3A) 18 1286 / 977 SMD 1.15 [0.68, 1.62] 96 < 0.00001 
LH (Fig 3B) 16 1171 / 846 SMD 1.29 [0.76, 1.83] 96 < 0.00001 
FSH (Fig 3C) 15 1098 / 782 SMD -0.02 [-0.49, 0.45] 95 0.94 
Anti-müllerian hormone (Fig 3D) 5 433 / 310 SMD 0.97 [0.60, 1.34] 76 < 0.00001 
Prolactin (Fig 3E) 5 310 / 193 SMD 0.80 [-0.55, 2.14] 98 0.25 
Estradiol (Fig 3F) 8 517 / 415 SMD -0.05 [-0.61, 0.51] 94 0.80 
Total testosterone (Fig 4A) 14 1019 / 783 SMD 2.58 [1.82, 3.35] 98 < 0.00001 
Free testosterone (Fig 4B) 7 632 /367 SMD 1.37 [0.56, 2.17] 96 0.0009 
DHEA-S (Fig 4C) 9 762 / 535 SMD 0.72 [0.32, 1.13] 91 0.0005 
SHBG (Fig 4 D) 7 632 / 367 SMD -1.34 [-2.15, -0.52] 96 0.001 
Ferriman-Gallweg score (Fig 4E) 5 563 / 474 SMD 5.08 [2.76, 7.39] 99 <0.0001 
Glucose (Fig 5A) 11 879 / 714 SMD 0.66 [-0.13, 1.43] 98 0.10 
HOMA-IR (Fig 5B) 10 840 / 558 SMD 0.76 [0.35, 1.17] 92 0.0003 
Insulin (Fig 5C)  8 627 / 477 SMD 0.75 [0.30, 1.19] 92 0.001 
Leptin (Fig 5D) 4 508 / 324 SMD 2.82 [1.35, 4.29] 98 0.0002 
Total cholesterol (Fig 6A) 4 542 / 415 SMD 0.60 [-0.12, 1.33] 96 0.10 
HDL-cholesterol (Fig 6B) 4 542 / 415 SMD -0.43 [-1.02, 0.16] 95 0.15 
LDL-cholesterol (Fig 6C) 4 542 / 415 SMD 0.75 [-0.32, 1l81] 98 0.17 





Table 3. Sensitivity analyses (by excluding one trial at one time) reporting SMD and 95% 
confidence interval (CI), and I2 for circulating kisspeptin,  HOMA-IR index and AMH when 




SMD (95%CI); I2 
HOMA-IR index 
SMD (95%CI); I2 
AMH 
SMD (95%CI); I2 
Al-Jelawy ZH 2019 [29,30] 0.82 (0.43, 1.22); 94% - - 
Anim-Ankumah A 2019 [31] 0.99 (0.54, 1.43);  95% - - 
Branavan U 2019 [32] 0.91 (0.52, 1.29); 94% - - 
Celik N 2018 [33] 1.21 (0.72, 1.70); 96% 0.75 (0.31, 1.19); 92% - 
Chen X 2010 [34] 1.21 (0.72, 1.70); 96% 0.77 (0.33, 0.41); 92% - 
Daghestani MH 2020 [35] 1.23 (0.72, 1.73); 96% - - 
El-Shehawy YM 2016 [36] 1.21 (0.72, 1.70); 96% - 0.85 (0.50, 1.21) 74% 
Emekci Ozay OE [37] 1.23 (0.70, 1.75); 96% 0.77 (0.26, 1.27) 92% 1.02 (0.46, 1.58) 82% 
Gorkem U, 2018 [38] 1.20 (0.70, 1.70); 96% - 0.89 (0,46, 1.33) 78% 
Ibrahim RO 2020 [39] 1.18 (0.68, 1.68); 96% - - 
Jeon YE 2013 [40] 1.18 (0.68, 1.67); 96% 0.75 (0.30, 1.20) 92% - 
Kaya C 2018 [41] 1.15 (0.66, 1.64); 96% - 1.1. (0.81, 1.42) 61% 
Mut A 2020 [42] 1.22 (0.72, 1.72); 96% 0.78 (0.21, 1.24) 92% 0.98 (0.48, 1.48) 82% 
Nyagolova PV 2016 [43] 1.20 (0.71, 1.70); 96% 0.55 (0.28, 0.83) 80% - 
Panidis D 2006 [44] 1.23 (0.75, 1.72); 96% 0.86 (0.44, 1.28) 92% - 
Rashad NM 2019 [45] 1.21 (0.70, 1.72); 96% 0.70 (0.26, 1.13) 91% - 
Wang T 2019 [46] 1.22 (0.72, 1.72); 96% 0.81 (0.35, 1.26) 92% - 
Yilmaz SA 2014 [47] 1.16 (0.66, 1.65); 96% 0-84 (0.40, 1.27) 91% - 
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eMethods 1. Pubmed search strategy. 
 
"polycystic ovary syndrome"[MeSH Terms] OR "polycystic ovary syndrome"[Tiab] OR 
"Polycystic Ovarian Syndrome"[tiab] OR "sclerocystic ovary syndrome"[Tiab] OR "ovary 
polycystic disease"[tiab] OR "polycystic ovarian syndrome"[Tiab] OR "syndrome 
polycystic ovary"[Tiab] OR "stein leventhal syndrome"[Tiab] OR ("polycystic"[Tiab] AND 
"ovary"[Tiab] AND "syndrome"[Tiab]) OR ("stein"[Tiab] AND "leventhal"[Tiab] AND 
"syndrome"[Tiab]) AND "kisspeptins"[MeSH Terms] OR "kisspeptins"[Tiab] OR 
"metastasis suppressor kiss 1"[Tiab] OR "kisspeptin s"[Tiab] OR "kisspeptin"[Tiab] OR 
"kiss 1 metastasis suppressor"[Tiab] OR "metastin"[tiab] OR "receptors, kisspeptin-




























Same method of 
ascertainment  
Statistical test  
Non-response 
rate 
Aljelawy ZH 2019 [29,30] 1 1 1 1 0 1 0 0 5 
Anim-Ankumah A 2019 [31] 1 1 0 1 0 1 1 0 5 
Branavan U 2019 [32] 1 1 0 1 0 1 1 0 5 
Celik N 2018 [33] 1 1 1 1 0 1 1 0 6 
Chen X 2010 [34] 1 1 1 1 0 1 1 0 6 
Daghestani MH 2020 [35] 1 1 1 1 0 1 1 1 7 
El-Shehawy YM 2016 [36] 1 1 1 1 1 1 1 0 7 
Emekci Ozay OE 2016 [37]   1 1 1 1 1 1 1 1 8 
Gorkem U, 2018 [38] 1 1 1 1 1 1 1 0 7 
Ibrahim RO 2020 [39] 1 1 1 1 1 1 1 0 7 
Jeon YE 2013 [40] 1 1 1 1 0 1 1 1 7 
Kaya C 2018 [41] 1 1 1 1 0 1 1 1 7 
Mut A 2020 [42] 1 1 1 1 0 1 1 1 7 
Nyagolova PV 2016 [43] 1 1 1 1 0 1 1 1 7 
Panidis D 2006 [44] 1 1 1 1 0 1 1 1 7 
Rashad NM 2019 [45] 1 1 1 1 1 1 1 1 8 
Wang T 2019 [46] 1 1 1 1 0 1 1 1 7 




eTable 2. Publication bias assessment for outcomes reported in at least 10 studies, 
Egger’s regression, and Kendall’s tau. 
 
Outcomes Studies (n) Egger’s test; p Kendall’s tau; p 
Age 18 0.122; 0.903 -0.359; < 0.001 
BMI 18 0.371; 0.711 -0.371; 0.881 
Kisspeptin 18 7.535; <0.001 0.373; 0.032 
Kisspeptin (^) 15 - 0.172; 0.863 0.124; 0.559 
LH 16 5.042; <0.001 0.367; 0.052 
FSH 15 3.461; <0.001 0.219; 0.282 
Estradiol  15 -1.022; 0.307 0.071; 0.905 
Testosterone 14 10.607; <0.001 0.429; 0.036 
Glucose 12 1.145; 0.252 0.182; 0.459 
HOMA-IR 10 0.136; 0.892 0.111; 0.727 
 







eSupplementary figure 1. Subgroup analysis of circulating kisspeptin levels including 




eSupplementary figure 2. Subgroup analysis of circulating kisspeptin levels including 




eSupplementary figure 3. Subgroup analysis of circulating kisspeptin levels including 








eSupplementary figure 4. Meta-regression analyses on the effect of age (Figure 4A, p = 
0.356), HOMA-IR index (Figure 4B, p = 0.930), insulin (Figure 4C, p = 0.898), AMH (Figure 
4D, p = 0.64), and LH (Figure 4E, p = 0.998) on circualting kisspeptin levels. 
 
 








































eSupplementary figure 5. Sensitivity analysis for kisspeptin levels by deleting 4 studies. 









eSupplementary figure 6. Publication bias assessment for circulating kisspeptin in women 
with and without PCOS (n = 18 studies; top) and after deleting 3 studies (bottom) with 
publication bias [29, 31, 32]. The table summarizes Kendall’s tau and Egger’s test values.  
 
(6a) 18 studies 
      
 





 Kisspeptin n= 18 
studies 
Kisspeptin deletting 3 studies [29, 31, 
32] (with suspected publication bias) 
Test name Value p Value p 
Fail-safe n 1847.0 < 0.001 404.0 < 0.001 
Kendalls Tau 0.373 0.032 0.124 0.559 
Egger's Regression 7.535 < 0.001 -0.172 0.863 
Trim and Fill Number of 
Studies 







eSupplementary figure 7. Publication bias assessment for HOMA-IR index in women with 




 HOMA-IR index n = 10 studies  
Test name Value p 
Fail-safe n 522.0 < 0.001 
Kendalls Tau 0.111 0.727 
Egger's Regression 0.136 0.892 
Trim and Fill Number of Studies 0  
 
 
 
